| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
SC-435 mesylate targets the ileal apical sodium co-dependent bile acid transporter (ASBT). ASBT is responsible for the reabsorption of bile acids from the intestine back into the liver. By inhibiting this transporter, SC-435 prevents bile acid reabsorption, which leads to increased bile acid synthesis from cholesterol in the liver, thereby lowering plasma cholesterol levels.
|
|---|---|
| ln Vitro |
SC-435 mesylate is a potent inhibitor of ASBT. Its in vitro activity is characterized by its ability to inhibit the transport of bile acids by ASBT. This leads to a reduction in plasma cholesterol levels, as confirmed in preclinical studies. Specific IC50 values are not provided in the search results.
|
| ln Vivo |
SC-435 mesylate has demonstrated in vivo efficacy in lowering plasma cholesterol. It alters hepatic cholesterol metabolism and lowers plasma low-density lipoprotein-cholesterol concentrations. This confirms its activity as a cholesterol-lowering agent in animal models. The compound is an orally active inhibitor.
|
| Enzyme Assay |
The in vitro activity of SC-435 mesylate is typically assessed using cell-based or membrane-based assays that measure the transport of bile acids. The compound's ability to inhibit ASBT-mediated bile acid uptake is measured. These assays are used to determine its potency and selectivity for the transporter.
|
| Cell Assay |
Cell-based assays are used to evaluate SC-435 mesylate's activity. Cells expressing the ASBT transporter are incubated with a labeled bile acid in the presence of various concentrations of the compound. The amount of labeled bile acid taken up into the cells is measured, and the extent of inhibition is calculated.
|
| Animal Protocol |
In vivo studies are conducted in animal models of hypercholesterolemia. SC-435 mesylate is typically administered orally, and its effects on plasma cholesterol levels, lipoprotein profiles, and hepatic cholesterol metabolism are measured. These studies confirm its efficacy as a cholesterol-lowering agent.
|
| ADME/Pharmacokinetics |
SC-435 mesylate has a molecular weight of 722.01 and a molecular formula of C37H59N3O7S2. Its purity is 98%. It is an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor. It inhibits plasma cholesterol. The compound is also known as SC-435.
|
| Toxicity/Toxicokinetics |
SC-435 mesylate is a research compound for studying cholesterol metabolism. Its toxicity profile is not detailed in the provided sources. As an inhibitor of bile acid reabsorption, it could potentially cause gastrointestinal side effects. However, in preclinical studies, it was tolerated at the doses used to demonstrate efficacy.
|
| References | |
| Additional Infomation |
SC-435 mesylate (CAS#: 289037-67-8) is a potent inhibitor of the ileal apical sodium co-dependent bile acid transporter (ASBT). It alters hepatic cholesterol metabolism and lowers plasma low-density lipoprotein-cholesterol concentrations. SC-435 mesylate is an orally active compound used as a research tool for studying cholesterol metabolism and as a potential therapeutic agent for hypercholesterolemia.
|
| Molecular Formula |
C36H56N3O4S+.CH3O3S-
|
|---|---|
| Molecular Weight |
722.01026
|
| Exact Mass |
721.379
|
| CAS # |
289037-67-8
|
| Related CAS # |
289037-67-8 (mesylate);289037-66-7 (cation);460041-92-3 (undefined isomer);460041-91-2 (undefined isomer cation);
|
| PubChem CID |
9918279
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
49
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)C(C1O)C3=CC=C(C=C3)OCCCC[N+]45CCN(CC4)CC5)CCCC.CS(=O)(=O)[O-]
|
| InChi Key |
VRHOEJBXKXQDQB-SWIBWIMJSA-M
|
| InChi Code |
InChI=1S/C36H56N3O4S.CH4O3S/c1-5-7-17-36(18-8-6-2)28-44(41,42)33-16-13-30(37(3)4)27-32(33)34(35(36)40)29-11-14-31(15-12-29)43-26-10-9-22-39-23-19-38(20-24-39)21-25-39;1-5(2,3)4/h11-16,27,34-35,40H,5-10,17-26,28H2,1-4H3;1H3,(H,2,3,4)/q+1;/p-1/t34-,35-;/m1./s1
|
| Chemical Name |
(4R,5R)-5-[4-[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-yl)butoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1λ6-benzothiepin-4-ol;methanesulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~69.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3850 mL | 6.9251 mL | 13.8502 mL | |
| 5 mM | 0.2770 mL | 1.3850 mL | 2.7700 mL | |
| 10 mM | 0.1385 mL | 0.6925 mL | 1.3850 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
